Edition:
United States

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

2.55USD
20 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.55
Open
$2.55
Day's High
$2.60
Day's Low
$2.50
Volume
12,937
Avg. Vol
56,493
52-wk High
$6.45
52-wk Low
$2.05

Chart for

About

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02... (more)

Overall

Beta: --
Market Cap(Mil.): $65.01
Shares Outstanding(Mil.): 25.49
Dividend: --
Yield (%): --

Financials

  AXSM.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -1.29 -- --
ROI: -106.37 -0.74 13.19
ROE: -151.19 -2.80 15.00

BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer

* AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER

Apr 19 2018

BRIEF-Axsome Therapeutics Reports Q4 Loss Per Share $0.31

* AXSOME THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Mar 07 2018

BRIEF-Axsome Therapeutics Says Its CNS Disorder Candidate AXS-09 Met Main Goal Of Phase 1 Trial

* AXSOME THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 1 TRIAL OF NEXT GENERATION PRODUCT CANDIDATE AXS-09 CONTAINING CHIRALLY PURE ESBUPROPION AND DEXTROMETHORPHAN

Feb 26 2018

BRIEF-Axsome Therapeutics Says AXS-02 Independent Data Monitoring Committee Recommends Continuation Of COAST-1 Trial

* AXSOME THERAPEUTICS ANNOUNCES AXS-02 INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF COAST-1 TRIAL AND DISCONTINUATION OF CREATE-1 TRIAL

Jan 09 2018

BRIEF-Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics

* SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING Source text : [http://bit.ly/2jNkBHB] Further company coverage:

Dec 04 2017

BRIEF-Axsome Therapeutics Announces AXS-07 For The Treatment Of Migraine

* AXSOME THERAPEUTICS ANNOUNCES AXS-07 FOR THE TREATMENT OF MIGRAINE

Nov 28 2017

BRIEF-Axsome Therapeutics reports Q3 loss per share $0.27

* Axsome Therapeutics reports third quarter 2017 financial results

Nov 08 2017

Earnings vs. Estimates